Incyte Co. (INCY) Insider David W. Gryska Sells 6,760 Shares
Incyte Co. (NASDAQ:INCY) insider David W. Gryska sold 6,760 shares of the company’s stock in a transaction on Friday, January 5th. The shares were sold at an average price of $98.87, for a total transaction of $668,361.20. Following the completion of the sale, the insider now directly owns 20,752 shares of the company’s stock, valued at approximately $2,051,750.24. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Incyte Co. (INCY) traded down $4.52 during trading hours on Tuesday, reaching $96.29. 2,636,578 shares of the company were exchanged, compared to its average volume of 1,720,621. Incyte Co. has a 52 week low of $92.91 and a 52 week high of $153.15. The company has a quick ratio of 4.81, a current ratio of 4.82 and a debt-to-equity ratio of 0.01. The company has a market cap of $20,320.00, a price-to-earnings ratio of -120.36 and a beta of 0.74.
Incyte (NASDAQ:INCY) last posted its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.17 EPS for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.11. Incyte had a negative net margin of 10.90% and a negative return on equity of 12.91%. The company had revenue of $381.50 million during the quarter, compared to analyst estimates of $360.34 million. During the same period in the prior year, the business posted $0.19 EPS. The firm’s revenue was up 41.6% compared to the same quarter last year. research analysts predict that Incyte Co. will post -1.32 EPS for the current fiscal year.
A number of equities research analysts have recently issued reports on the stock. BMO Capital Markets reaffirmed an “outperform” rating and issued a $163.00 price objective (down previously from $172.00) on shares of Incyte in a research note on Monday, September 11th. Raymond James Financial raised shares of Incyte from a “market perform” rating to an “outperform” rating and set a $159.00 price objective for the company in a research note on Monday, September 11th. Argus reaffirmed a “buy” rating and issued a $150.00 price objective on shares of Incyte in a research note on Wednesday, September 13th. Royal Bank of Canada assumed coverage on shares of Incyte in a research note on Thursday, September 14th. They issued a “sector perform” rating and a $136.00 price objective for the company. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Incyte in a research note on Wednesday, October 25th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $143.11.
TRADEMARK VIOLATION WARNING: This story was published by American Banking News and is owned by of American Banking News. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/01/09/incyte-co-incy-insider-david-w-gryska-sells-6760-shares.html.
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.